Safety and pharmacokinetics of escalating doses of neutralising monoclonal antibody CAP256V2LS administered with and without VRC07-523LS in HIV-negative women in South Africa (CAPRISA 012B): a phase 1, dose-escalation, randomised controlled trial

Sharana Mahomed, Nigel Garrett, Edmund V. Capparelli, Farzana Osman, Nonhlanhla N. Mkhize, Ishana Harkoo, Tanuja N. Gengiah, Leila E. Mansoor, Cheryl Baxter, Derseree Archary, Nonhlanhla Yende‐Zuma, Natasha Samsunder, Kevin Carlton, Sandeep Narpala, Adrian B. McDermott, Nicole A. Doria‐Rose, Penny L. Moore, Lynn Morris, Quarraisha Abdool Karim, John R. Mascola, Salim S. Abdool Karim